CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 67 enrolled
Drug / intervention
Irinotecan +4 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01928290
NCT01928290Phase 2Completed
CompareCT.gov

Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors

Washington University School of Medicine·interventional·Posted Aug 23, 2013·Updated Aug 25, 2020

In Brief

A Phase 2 clinical trial evaluating Irinotecan, Trastuzumab, and 3 other interventions for Stomach Neoplasms and Esophageal Neoplasms. Completed, enrolled 67 participants across 1 site.

Detailed Summary

This phase II trial studies how well combination chemotherapy works in treating patients with advanced stomach, gastroesophageal, or esophageal cancer. Drugs used in chemotherapy, such as irinotecan hydrochloride, oxaliplatin, leucovorin calcium, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsStomach Neoplasms, Esophageal Neoplasms
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 23, 2013
Enrollment StartNov 8, 2013
Primary CompletionDec 3, 2018
Study CompletionOct 28, 2019
TodayJul 2, 2026
Enrollment to primary: 5.1 yearsPosted 12.9 years ago

Interventions

Irinotecandrug

Trastuzumabdrug

Oxaliplatindrug

Leucovorindrug

Fluorouracildrug